Physician profile
Judith Cabrera
NPI 1710202734
$2,646.49
in general payments reported to CMS, 2019-2025
23 companies · $90.99 in 2025
The $90.99 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $682 · 2024: $1,873 · 2025: $90.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,646.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $642.71 | 2023-2025 | |
| Viiv Healthcare Company | $564.30 | 2023-2025 | Apretude, Dovato |
| Genzyme Corporation | $235.26 | 2024 | |
| Edwards Lifesciences Corporation | $194.87 | 2023 | Sapien 3 Ultra Resilia |
| Organon LLC | $142.21 | 2024 | |
| Pfizer INC. | $116.56 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.62 | 2024-2025 | Xifaxan |
| Lilly USA, LLC | $89.84 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $83.97 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $76.55 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.99 | 2024 | |
| Phadia US INC. | $60.17 | 2023-2024 | Immunocap |
| Sanofi-Aventis U.S. LLC | $36.43 | 2024 | |
| Hologic Sales and Service, LLC | $31.39 | 2024 | Aptima |
| Emd Serono, INC. | $30.59 | 2023-2024 | Serostim |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $30.09 | 2024 | Veozah |
| Boston Scientific Corporation | $28.46 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $26.23 | 2023 | Rexulti |
| Dexcom, INC. | $24.77 | 2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $19.77 | 2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $17.78 | 2023 | Breztri |
| Halozyme INC | $16.16 | 2023 | |
| Antares Pharma, INC. | $13.77 | 2023 | Xyosted, Tlando, Nocdurna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.